Jingtao Ma

Dr. Jingtao Ma


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2025 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
JLJunli Lv
Junli Lv
ZTZhenzhen Tan
Zhenzhen Tan
ZAZiwen An
Ziwen An
RXRui Xu
Rui Xu
HZHuaxing Zhang
Huaxing Zhang
huicai Guohuicai Guo
huicai Guo

9 May 2024 in Toxicology Letters
Verified
Journal Article
Closed access
HYHaichao Yang
Haichao Yang
SQSuhua Qiu
Suhua Qiu
TYTiezhu Yao
Tiezhu Yao
GLGuang Liu
Guang Liu
JLJing Liu
Jing Liu
JMJingtao Ma
Jingtao Ma

27 May 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
ZLZhenli Li
Zhenli Li
TYTiezhu Yao
Tiezhu Yao
GLGuang Liu
Guang Liu
ZGZhengkun Guan
Zhengkun Guan
JLJing Liu
Jing Liu
JMJingtao Ma
Jingtao Ma
Purpose: Immune checkpoint inhibitors-related myocarditis (ICI-M) is one of the immune-related adverse events (irAEs), which is rare and highly lethal. This study aimed to establish nomograms based on ratio biomarkers to predict the severity and prognosis of ICI-M. Methods: We retrospectively examined patients with advanced cancers who were also diagnosed with ICI-M at the Fourth Hospital of Hebei Medical University. The patients of ICI-M were divided into mild and severe groups and a 40-day following up was carried out. The major adverse cardiovascular events(MACEs) were regarded as the endpoint. Nomogram-based models were established and validated. Results: Seventy-seven patients were involved, including 31 severe cases(40.3%). Lactate dehydrogenase-to-albumin ratio(LAR) combined with the change rate from baseline to onset of LAR( $$\triangle$$ ▵ LAR) which performed best to diagnose the severe ICI-M was identified to establish the nomogram-based model. The bootstrap-corrected concordance index [0.752 95% confidence interval (CI): 0.635 $$-$$ - 0.866] and calibration plot with good degree of fitting confirmed this diagnostic model. Neutrophil-to-high-density lipoprotein cholesterol ratio(NHR) and LAR were also screened into the nomogram-based model for 40-day MACEs after ICI-M, which performed well by validating for concordance index(0.779 95% CI: 0.677 $$-$$ - 0.865)and calibration plots after being bootstrap-corrected. Moreover, a $$\ge$$ ≥ 101% increase in LAR significantly separated patients in MACE-free survival. Conclusion: Ratio indexes at onset and their change rates from baseline showed good diagnostic value for the severity of ICI-M and prognostic value for subsequent MACEs, particularly LAR, NHR and their change rates. The nomogram-based models of ratio indexes could provide a potential choice for early detection and monitor of the severe ICI-M and subsequent MACEs. Graphical

1 January 2024 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
JLJing Liu
Jing Liu
RLRuobei Li
Ruobei Li
TYTiezhu Yao
Tiezhu Yao
GLGuang Liu
Guang Liu
LGLing Guo
Ling Guo
ZLZhenli Li
Zhenli Li
Background: Pulmonary embolism (PE) patients combined with heart failure (HF) have been reported to have a high short-term mortality. However, few studies have developed predictive tools of 30-day mortality for these patients in intensive care unit (ICU). This study aimed to construct and validate a machine learning (ML) model to predict 30-day mortality for PE patients combined with HF in ICU. Methods: We enrolled patients with PE combined with HF in the Medical Information Mart for Intensive Care Database (MIMIC) and developed six ML models after feature selection. Further, eICU Collaborative Research Database (eICU-CRD) was utilized for external vali- dation. The area under curves (AUC), calibration curves, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were performed to evaluate the prediction performance. Shapley additive explanation (SHAP) was performed to enhance the interpretability of our models. Results: A total of 472 PE patients combined with HF were included. We developed six ML models by the 13 selected features. After internal validation, the Support Vector Ma- chine (SVM) model performed best with an AUC of 0.835, a superior calibration degree, and a wider risk threshold (from 0% to 90%) for obtaining clinical benefit, which also outperformed traditional mortality risk evaluation systems,as evaluated by NRI and IDI. The SVM model was still reliable after external validation. SHAP was performed to explain the model. Moreover, an online application was developed for further clinical use. Conclusion: This study developed a potential tool for identify short-term mortality risk to guide clinical decision making for PE patients combined with HF in the ICU. The SHAP method also helped clinicians to better understand the model.

27 February 2026 in Medicine
Verified
Journal Article
Open access
SLSihan Liu
Sihan Liu
JMJingtao Ma
Jingtao Ma
ZLZhenli Li
Zhenli Li
MLMengjia Bs Li
Mengjia Bs Li
TWTenghui Bs Wang
Tenghui Bs Wang
GLGuang Liu
Guang Liu
The gut microbiota, particularly genus Ruminiclostridium6 , has been implicated in modulating immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy. However, the mediating roles of circulating metabolites and cytokines in this relationship remain poorly understood. We performed a two-sample Mendelian randomization study to investigate causal links between genus Ruminiclostridium6 , 19 plasma metabolites, 41 cytokines, and high-grade irAEs. Genetic instruments were selected from publicly available genome-wide association studies summary statistics. Inverse variance weighted method served as the primary analysis, supplemented by sensitivity and mediation analyses. No robust causal relationships were found between genus Ruminiclostridium6 and the 19 metabolites. However, high-grade irAEs were causally linked to decreased oleoylcholine levels. Among cytokines, only IL-2RA showed a causal association with high-grade irAEs, but not with genus Ruminiclostridium6 . Consequently, two-step Mendelian randomization did not support a mediating role for the studied metabolites or cytokines in the genus Ruminiclostridium6 –irAEs pathway. Enrichment analysis highlighted glycine, serine, threonine, arginine, and proline metabolism as potential pathways of interest. This study did not support 19 plasma metabolites or 41 cytokines as major mediators of the protective effect of genus Ruminiclostridium6 against high-grade irAEs. The mechanism may involve local gut-level immunomodulation or microbial metabolites not captured in this study. These findings underscore the complexity of microbiota–irAEs interactions and highlight specific metabolic pathways for further investigation.

7 November 2025 in Medicine
Verified
Journal Article
Open access
LGLing Guo
Ling Guo
CNCongying Ni
Congying Ni
JMJingtao Ma
Jingtao Ma
ZLZhenli Li
Zhenli Li
Emerging evidence suggests a potential link between gut microbiota and cardiomyopathies, but the causal relationships and the mediating role of cytokines remain unclear. We performed a two-sample Mendelian randomization (MR) analysis using genome-wide association study (GWAS) summary data for 211 gut microbiota taxa, 41 cytokines, and cardiomyopathy subtypes. Instrumental variables were selected at a genome-wide significance threshold ( P < 1 × 10 −5 ). Primary causal estimates were derived via inverse-variance weighted (IVW) regression, supplemented by sensitivity analyses. Multivariable MR was utilized to reduce bias from confounders. Mediation analysis tested whether cytokines linked gut microbiota to cardiomyopathies. Genetic liability in gut microbiota showed significant associations with cardiomyopathy risk. For dilated cardiomyopathy (DCM), genus Ruminococcaceae (OR = 1.24, 95% CI: 1.00–1.54, P = .045) and genus Flavonifractor (OR = 1.66, 95% CI: 1.15–2.35, P = .0067) increased risk, while family Peptostreptococcaceae was protective (OR = 0.71, 95% CI: 0.51–0.99, P = .041). For hypertrophic cardiomyopathy (HCM), genus Enterorhabdus raised risk (OR = 1.53, 95% CI: 1.00–2.33, P = .049), whereas order Methanobacteria lowered it (OR = 0.69, 95% CI: 0.52–0.93, P = .013). For myocarditis, genus Faecalibacterium reduced risk (OR = 0.53, 95% CI: 0.33–0.85, P = .009), but genus Family XIII UCG001 increased it (OR = 2.06, 95% CI: 1.15–3.69, P = .015). Cytokines including IL-9 and MIP-1β showed protective effects for DCM, while pro-inflammatory cytokines TNF-α and VEGF elevated myocarditis risk. Mediation analysis revealed cytokines did not mediate gut microbiota-cardiomyopathy pathways. Specific gut microbiota and cytokines exert causal effects on cardiomyopathy subtypes, independent of cytokine mediation. These findings highlight potential therapeutic targets and underscore the need to explore alternative mechanistic pathways.